Prospect of Using Cell Product for the Therapy of Skin Defects in Diabetes Mellitus

A. P. Lykov; N. A. Bondarenko; O. V. Poveshchenko; T. V. Miller; A. F. Poveshchenko; M. A. Surovtseva; N. P. Bgatova; V. I. Konenkov

doi:10.1007/s10517-017-3970-0

Prospect of Using Cell Product for the Therapy of Skin Defects in Diabetes Mellitus

Authors: Lykov A.P.¹^,2, Bondarenko N.A.¹^,2, Poveshchenko O.V.¹^,2, Miller T.V.¹, Poveshchenko A.F.¹^,2, Surovtseva M.A.¹^,2, Bgatova N.P.¹, Konenkov V.I.¹
Affiliations:
1. Research Institute of Clinical and Experimental Lymphology
2. E. N. Meshalkin Research Institute of Circulatory Pathology, Ministry of Health of the Russian Federation
Issue: Vol 164, No 2 (2017)
Pages: 266-268
Section: Translated from Kletochnye Tekhnologii v Biologii i Meditsine (Cell Technologies in Biology and Medicine)
URL: https://journals.rcsi.science/0007-4888/article/view/239545
DOI: https://doi.org/10.1007/s10517-017-3970-0
ID: 239545

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Statistics

Abstract

The effectiveness of autologous cell product in the therapy of skin burn wounds was studied in C57B1/6 male mice against the background of streptozotocin-induced diabetes mellitus. In animals with and without modeled diabetes mellitus, significant decrease in skin defect area was observed after single administration of the cell product (bone marrow multipotent mesenchymal stromal cells, fibroblasts or media conditioned by these cells).